Blood Reviews

Article	Citations
Bridging the evidence-to-practice gap: Advancing neonatal blood transfusion. A narrative review of recent guidelines	151
Thalassaemia in China	110
Radiation and leukaemia: Which leukaemias and what doses?	108
The impact of ABO blood group on COVID-19 infection risk and mortality: A systematic review and meta-analysis	106
Classic Hodgkin lymphoma: Pathobiological features that impact emerging therapies	97
Editorial Board	86
Practical considerations in clinical application of WHO 5th and ICC classification schemes for acute myeloid leukemia	77
Beyond current treatment of Fanconi Anemia: What do advances in cell and gene-based approaches offer?	64
Philadelphia chromosome-negative myeloproliferative neoplasms in younger adults: A critical discussion of unmet medical needs, with a focus on pregnancy	60
Expanding post-transplant cyclophosphamide to matched unrelated donor transplants and beyond	56
Putting function back in dysfunction: Endothelial diseases and current therapies in hematopoietic stem cell transplantation and cellular therapies	52
Hematopoietic versus leukemic stem cell quiescence: Challenges and therapeutic opportunities	50
Editorial Board	49
Host-directed therapies modulating innate immunity against infection in hematologic malignancies	47
Maternal and neonatal bleeding complications in relation to peripartum management in hemophilia carriers: A systematic review	44
TP53 in AML and MDS: The new (old) kid on the block	40
Biologic therapies for hypereosinophilic disorders: From tyrosine kinase inhibitors to monoclonal antibodies. Towards an increasingly customized management?	40
When hematologic malignancies meet COVID-19 in the United States: Infections, death and disparities	38
Management of transfusion-dependent β-thalassemia (TDT): Expert insights and practical overview from the Middle East	36
Cell therapy of chronic lymphocytic leukaemia: Transplants and chimeric antigen receptor (CAR)-T cells	36
Artificial intelligence in sickle disease	36
Getting blood out of a stone: Identification and management of patients with poor hematopoietic cell mobilization	35
Pitfalls in laboratory monitoring of treatment in people with Haemophilia	35
Not all LGL leukemias are created equal	33
Regulatory T cell niche in the bone marrow, a new player in Haematopoietic stem cell transplantation	33

Androgen use in bone marrow failures and myeloid neoplasms: Mechanisms of action and a systematic review of clinical data	32
Clinical burden of hemophilia in older adults: Beyond bleeding risk	31
Neuro-toxicities of chemo- and immune-therapies in haematologic malignancies: from mechanism to management	31
Editorial Board	31
Platelet transfusion refractoriness due to HLA alloimmunization: Evolving paradigms in mechanisms and management	31
Ex vivo expansion of hematopoietic stem cells: Finally transitioning from the lab to the clinic	29
Bispecific antibody therapy, its use and risks for infection: Bridging the knowledge gap	29
The structure, function, and clinical use of the thrombopoietin receptor agonist avatrombopag	29
Biomarkers and laboratory assessments for monitoring the treatment of patients with paroxysmal nocturnal hemoglobinuria: Differences between terminal and proximal complement inhibition	28
The recipe for TACO: A narrative review on the pathophysiology and potential mitigation strategies of transfusion-associated circulatory overload	28
Molecular basis of rare congenital bleeding disorders	27
Metabolic regulation of the bone marrow microenvironment in leukemia	27
Targeting apoptosis dysregulation in myeloid malignancies - The promise of a therapeutic revolution	27
Clinical features and treatment strategies for post-transplant and iatrogenic immunodeficiency-associated lymphoproliferative disorders	27
Longitudinal clinical manifestations of Fanconi anemia: A systematized review	26
Exploiting the ubiquitin system in myeloid malignancies. From basic research to drug discovery in MDS and AML	26
Free of malignancy but not of fears: A closer look at Damocles syndrome in survivors of hematologic malignancies	25
Long-term safety review of tyrosine kinase inhibitors in chronic myeloid leukemia - What to look for when treatment-free remission is not an option	24
Targeting cereblon in hematologic malignancies	24
A new era in oxygen therapeutics? From perfluorocarbon systems to haemoglobin-based oxygen carriers	24
Hemophilia treatment in 2021: Choosing the”optimal” treatment using an integrative, patient-oriented approach to shared decision-making between patients and clinicians	23
Knowing the unknowns in high risk multiple myeloma	23
Health related quality of life in children with sickle cell disease: A systematic review and meta-analysis	22
Disparity in hematological malignancies: From patients to health care professionals	21
Hemostatic changes by thrombopoietin-receptor agonists in immune thrombocytopenia patients	21
The landscape of immune monitoring in CAR-T cell therapy: A comprehensive review and survey study by the Cellular Therapy and Immunobiology Working Party of the EBMT	21
Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): A state-of-the-art report on behalf of the International Consortium for MDS (icMDS)	21
BTK inhibitors resistance in B cell malignancies: Mechanisms and potential therapeutic strategies	20
The fear for adverse bleeding and cardiovascular events in hemophilia patients using (non-)selective non-steroidal anti-inflammatory drugs: A systematic review reporting on safety	20
BTKi-induced cardiovascular toxicity in CLL: Risk mitigation and management strategies	20
Failure of CAR-T cell therapy in relapsed and refractory large cell lymphoma and multiple myeloma: An urgent unmet need	19
Clinical overview and practical considerations for optimizing romiplostim therapy in patients with immune thrombocytopenia	19
Ven the dose matters: Venetoclax dosing in the frontline treatment of AML	19
Aiming for the cure in myeloma: Putting our best foot forward	18
Beyond steroids: A systematic review and proposed solutions to managing acute graft-versus-host disease in adolescents and young adults	18
Innovations in red blood cell preservation	18
Game of clones: Diverse implications for clonal hematopoiesis in lymphoma and multiple myeloma	18
Blasts in context: the impact of the immune environment on acute myeloid leukemia prognosis and treatment	18
Addressing the challenges of accelerated and blast phase myeloproliferative neoplasms in 2022 and beyond	18
Nothing short of a revolution: Novel extended half-life factor VIII replacement products and non-replacement agents reshape the treatment landscape in hemophilia A	17
Autoantibodies in immunodeficiency syndromes: The Janus faces of immune dysregulation	17
Editorial Board	17
Heartbreaker: Detection and prevention of cardiotoxicity in hematological malignancies	17
Smoldering multiple myeloma – Past, present, and future	16
No apparent association between mRNA COVID-19 vaccination and venous thromboembolism	16
Editorial Board	16
Primary and secondary immune thrombocytopenia (ITP): Time for a rethink	15
Allogeneic hematopoietic stem cell transplant for sickle cell disease: The why, who, and what	15
Brain-derived neurotrophic factor in hematological malignancies: From detrimental to potentially beneficial	15
Advances in the management of TTP	15

Chasing leukemia differentiation through induction therapy, relapse and transplantation	15
PET scan for the detection of histological transformation of follicular lymphoma: A systematic review of diagnostic performance	14
The development of post-transplant cyclophosphamide: Half a century of translational team science	14
Does PTCY increase the risk of infections?	14
An owner's manual for CD19 “CAR”-T cell therapy in managing pediatric and young adult B-cell acute lymphoblastic leukemia	13
Corrigendum to “Activation of pyruvate kinase as therapeutic option for rare hemolytic anemias: Shedding new light on an old enzyme” [Blood Rev. 2023 Sep:61:101103]	13
A review of pathobiology and therapies for classic Hodgkin lymphoma	13
Genetic landscape in coagulation factor XIII associated defects – Advances in coagulation and beyond	13
l-glutamine, crizanlizumab, voxelotor, and cell-based therapy for adult sickle cell disease: Hype or hope?	13
Depression in patients with hematologic malignancies: The current landscape and future directions	12
Follicular lymphoma: The long and winding road leading to your cure?	12
Quality of life, mood disorders, and cognitive impairment in adults with β-thalassemia	12
Thrombotic events associated with immune checkpoint inhibitors and novel antithrombotic strategies to mitigate bleeding risk	12
Breaking down frailty: Assessing vulnerability in acute myeloid leukemia	12
Autologous stem cell transplantation in AL amyloidosis: Muddy waters	12
Low flow: Selecting a limited flow cytometry panel where resources are constrained	12
Management of infection in PNH patients treated with eculizumab or other complement inhibitors: Unmet clinical needs	12
Relapse after allogeneic transplantation with post-transplant cyclophosphamide: Shattering myths and evolving insight	11
Central nervous system prophylaxis in diffuse large B-cell lymphoma: What does the evidence tell us?	11
Systematic review of staging bone marrow involvement in B cell lymphoma by flow cytometry	11
No needles needed: All-oral therapy options for relapsed and refractory multiple myeloma	11
Inherited thrombocytopenias: an updated guide for clinicians	11
Diagnosis, therapeutic advances, and key recommendations for the management of factor X deficiency	11
Historical perspective and a glance into the antibody-based conditioning regimens: A new era in the horizon?	10
FLT3 mutational analysis in acute myeloid leukemia: Advantages and pitfalls with different approaches	10
Insights on chronic immune thrombocytopenia pathogenesis: A bench to bedside update	10
When anticoagulation management in atrial fibrillation becomes difficult: Focus on chronic kidney disease, coagulation disorders, and cancer	10
COVID-19 breakthrough infections, hospitalizations and mortality in fully vaccinated patients with hematologic malignancies: A clarion call for maintaining mitigation and ramping-up research	10
Unraveling germline predisposition in hematological neoplasms: Navigating complexity in the genomic era	10
Fetal and neonatal alloimmune thrombocytopenia: Current pathophysiological insights and perspectives for future diagnostics and treatment	10
Decoding DNA methylation in epigenetics of multiple myeloma	10
Gut microbiome composition and dysbiosis in immune thrombocytopenia: A review of literature	10
Biochemical marker research in hemophilic arthropathy: A systematic review	10
Novel agents for the treatment of lymphomas during pregnancy: A comprehensive literature review	10
Endothelial cells: major players in acute myeloid leukaemia	10
One arrow for two targets: potential co-treatment regimens for lymphoma and HIV	10
A personalized, organ-based approach to the treatment of chronic steroid-refractory graft-versus-host disease	10
Future prospects for the clinical transfusion of pig red blood cells	9
Discussing investigational AAV gene therapy with hemophilia patients: A guide	9
Perspective – The case for zero bleeds and drug bioequivalence in the treatment of congenital hemophilia A in 2021	9
Recent advances in neutropenic enterocolitis: Insights into the role of gut microbiota	9
Targeting hematologic malignancies by inhibiting E-selectin: A sweet spot for AML therapy?	9
The use of bone-modifying agents in multiple myeloma	9
The association between excess body weight at diagnosis and pediatric leukemia prognosis: A systematic review and meta-analysis	9
Coagulation and anticoagulation in COVID-19	9
Past, present and future of prognostic scores in follicular lymphoma	8
Continuing progress in radioimmunotherapy for hematologic malignancies	8
Tailoring oral anticoagulant treatment in the era of multi-drug therapies for PAH and CTEPH	8
Absolute and functional iron deficiency: Biomarkers, impact on immune system, and therapy	8
Diagnosis of infectious diseases in immunocompromised hosts using metagenomic next generation sequencing-based diagnostics	8
Progress, and prospects in the therapeutic armamentarium of persons with congenital hemophilia. Defining the place for liver-directed gene therapy	8
Gut dysbiosis, endotoxemia and clotting activation: A dangerous trio for portal vein thrombosis in cirrhosis	8
Mechanisms of myeloid leukemogenesis: Current perspectives and therapeutic objectives	8
Harnessing multi-source data for individualized care in Hodgkin Lymphoma	8
The future of research in hematology: Integration of conventional studies with real-world data and artificial intelligence	8
Revolutionizing chronic lymphocytic leukemia diagnosis: A deep dive into the diverse applications of machine learning	8
How do we improve the translation of new evidence into the practice of hematopoietic cell transplantation and cellular therapy?	7
The acute pain crisis in sickle cell disease: What can be done to improve outcomes?	7
Advances in NK cell therapy for hematologic malignancies: NK source, persistence and tumor targeting.	7
Platelet factor 4(PF4) and its multiple roles in diseases	7
Post-transplantation cyclophosphamide as GVHD prophylaxis in allogenic hematopoietic stem cell transplantation: Recent advances and modification	7
Revolutionising healing: Gene Editing's breakthrough against sickle cell disease	7
Neoantigens – the next frontier in precision immunotherapy for B-cell lymphoproliferative disorders	7
Transfusion-related acute lung injury (TRALI): Potential pathways of development, strategies for prevention and treatment, and future research directions	7
Coagulopathy and sepsis: Pathophysiology, clinical manifestations and treatment	7
Chronic Myeloid Leukemia: Modern therapies, current challenges and future directions	7
Nodal peripheral T-cell lymphoma: Chemotherapy-free management, are we there yet?	7
Immunity reloaded: Deconstruction of the PD-1 axis in B cell lymphomas	7
Immune thrombocytopenia: A review of upfront treatment strategies	7
BCL-2 inhibition in haematological malignancies: Clinical application and complications	7
Clinical outcomes of COVID-19 in patients with sickle cell disease and sickle cell trait: A critical appraisal of the literature	7
Preservation of fertility in female patients with hematologic diseases	6
The road to implementation of pharmacokinetic-guided dosing of factor replacement therapy in hemophilia and allied bleeding disorders. Identifying knowledge gaps by mapping barriers and facilitators	6
Current approach to Waldenström macroglobulinemia	6
CHIPing away the progression potential of CHIP: A new reality in the making	6
Myeloid sarcoma, chloroma, or extramedullary acute myeloid leukemia tumor: A tale of misnomers, controversy and the unresolved	6
The extracellular matrix: A key player in the pathogenesis of hematologic malignancies	6
From microscope to micropixels: A rapid review of artificial intelligence for the peripheral blood film	6
Haploidentical transplantation: An optimal platform for graft manipulation and cellular therapies	6
Thalassemia and autoimmune diseases: Absence of evidence or evidence of absence?	6

Antibiotics to modify sickle cell disease vaso-occlusive crisis?

6